Merck KGaA Q3 2026 results show solid growth, with Group net sales rising 5.1% organically to €5.6 billion and the company lifting its full-year 2026 guidance. The announcement, issued on 12 November 2026 from Darmstadt, Germany, credits Process Solutions, Rare Diseases and Semiconductor Solutions for the quarter’s performance.
EBITDA pre reached €1.7 billion, organically around stable at +0.4%, while earnings per share pre held at €2.32, level with the year-earlier quarter. According to the company, the flat organic EBITDA pre reflects a high comparison base, because Q3 2025 benefited from two one-time effects that each added a mid-double-digit million euro amount.
Kai Beckmann, Chairman of the Executive Board and Group CEO, said the quarter underscores the strength of the company’s integrated business model in attractive growth markets. In the Merck KGaA Q3 2026 results, the CEO pointed to biomanufacturing, semiconductor manufacturing that supports AI, and targeted specialty and rare diseases as priorities.
Merck KGaA Q3 2026 Results: Group Sales, Margins and Cash Flow at a Glance
Group net sales of €5.6 billion compared with €5.3 billion in Q3 2025, with organic growth of 5.1% supported by positive foreign exchange effects of 1.5%. The EBITDA pre margin was 29.9%, down from 31.4% a year earlier.
Free cash flow rose 22.7% to €1.3 billion, which supports deleveraging. Net financial debt fell 10.3% from the start of the year, to €7,733 million at the end of September. For investors tracking the Merck KGaA Q3 2026 results, cash generation stood out alongside organic sales growth.
On a reported basis, profit was lower. Operating result (EBIT) was €653 million versus €1,221 million a year earlier, and profit after income tax was €450 million versus €898 million. Earnings per share were €1.04 against €2.07; the press release does not explain these reported declines in detail.
All three business sectors increased net sales across regions and portfolios, with customer projects, capacity expansions and higher demand named as the main drivers. Asia-Pacific, at 34.8% of net sales, grew 12.1% and remained the largest market, followed by Europe at 29.1% and North America at 24.5%. Within the Merck KGaA Q3 2026 results, Life Science contributed 43% of sales, Healthcare 40% and Electronics 17%.
Merck KGaA Q3 2026 Results Show Life Science and Process Solutions Leading Growth
Life Science net sales reached €2.4 billion, up 6.1% organically, or 7.3% excluding tariff refunds to customers. EBITDA pre rose organically by 8.7% to €736 million. The sector increased R&D spending and bore startup costs for new manufacturing sites, including Daejeon, Korea, to support its region-for-region strategy.
Process Solutions, the main growth driver, grew 10.5% organically to €1,069 million, with strong demand across downstream processing, single-use solutions, and upstream and processing materials. The company notes that order book trends point to a softer fourth quarter, even as underlying demand and customer capacity expansion remain strong.
Discovery Solutions grew 1.7% organically to €722 million and Advanced Solutions grew 4.3% to €621 million. On the product side, the company cited MAST, an autosampler validated for commercial GMP production, new mConfig features for real-time trace element prediction, and the launch of SYNTHIA Agentic AI. The pending CDMO divestment to Lonza, expected to close in mid-2027, would sharpen Life Science’s portfolio focus, according to the company.
Merck KGaA Q3 2026 Results and Raised Guidance: Electronics, Silence Therapeutics and Bio-Techne Deals
Electronics delivered net sales of €948 million, up 13.3% organically, with EBITDA pre up 18.4% to €279 million. Semiconductor Solutions grew 18.7% organically on demand for advanced logic and memory nodes used in AI applications, while Optronics declined 0.9% as high memory chip prices weighed on consumer electronics demand. The company opened an R&D facility in Sheboygan, Wisconsin, under a US$200 million multi-year investment, and a molybdenum-based materials line in Eumseong, Korea.
Strategic moves also shape the Merck KGaA Q3 2026 results. In June 2026 the company agreed to acquire Bio-Techne for an enterprise value of about US$11.3 billion (€9.9 billion), and in October it agreed to acquire Silence Therapeutics, adding divesiran, a phase III-ready siRNA therapy for phlebotomy-dependent polycythemia vera dosed subcutaneously every three months. The Silence deal is expected to close in the first quarter of 2027.
For 2026, the company now expects net sales of €21.5 billion to €21.9 billion, EBITDA pre of €6.2 billion to €6.4 billion, EPS pre of €8.30 to €8.70 and free cash flow of about €2.3 billion to €2.7 billion. These forward-looking figures assume the Bio-Techne acquisition contributes in December 2026, which the company says may differ from the actual closing date, and no US Mavenclad sales from November 2026.
